Cartesian Therapeutics, Inc.

Cartesian’s direct customers are not patients in the commercial sense today; instead, its revenue comes mainly from pharmaceutical partners and grant providers. The company’s collaboration and license revenue reflects payments from counterparties such as Astellas under out-licensing arrangements, while grant revenue comes from organizations funding specific research and development work. If approved, its future commercial customers would be physicians, hospitals, and third-party payors treating autoimmune disease patients, especially in myasthenia gravis. Because the company has no sales or marketing infrastructure, any eventual product launch would likely require either a built commercial organization or a co-promotion/partner model.

Cartesian’s strategy is to advance Descartes-08 through late-stage clinical development and position its mRNA cell therapy platform as a differentiated approach to autoimmune disease. The company is also trying to preserve optionality through collaborations, licensing economics, and grant funding rather than relying on near-term product sales. Management emphasizes capital discipline because future funding needs will depend on trial scope, manufacturing scale-up, regulatory timing, and eventual commercialization costs. In the near term, the key strategic objective is to generate clinical and regulatory data strong enough to support a BLA submission and future market adoption.